

CITATION REPORT

List of articles citing

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

DOI: 10.1002/art.10141

Arthritis and Rheumatism, 2002, 46, 614-24.

Source: <https://exaly.com/paper-pdf/34513215/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
547	Soluble cytokine receptors in biological therapy. 2002 , 2, 585-605		32
546	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). 2002 , 61 Suppl 2, ii2-7		44
545	<i>Pseudomonas aeruginosa</i> activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 alpha and beta. 2002 , 169, 4522-30		71
544	Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. 2002 , 61, 960-7		58
543	Anakinra treatment of patients with rheumatoid arthritis. 2002 , 36, 1204-9		23
542	Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. 2002 , 61 Suppl 2, ii74-7		14
541	Using anakinra for adult rheumatoid arthritis. 2002 , 27, 62-5		2
540	Rheumatoid arthritis: developing pharmacological therapies. 2002 , 11, 927-35		7
539	Measurement of health-related quality of life in Rheumatology: Current concepts and controversies. 2002 , 40, 105-110		
538	Advances in the treatment of rheumatoid arthritis: old versus new therapies. 2002 , 3, 845-56		16
537	Anakinra: profile report. 2002 , 18, 4-6		
536	Anakinra. <i>BioDrugs</i> , 2002 , 16, 303-11; discussion 313-4	7.9	40
535	Anakinra. <i>BioDrugs</i> , 2002 , 16, 313-314	7.9	1
534	The balance between IL-1 and IL-1Ra in disease. 2002 , 13, 323-40		530
533	[Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist]. 2002 , 23, 1006-11		3
532	Anakinra shows promise for treating patients with rheumatoid arthritis. 2002 , 42, 660-2		6
531	Options for blocking interleukin-1 in patients with rheumatoid arthritis. 2002 , 69, 351-4		1

530	Targeting interleukin-1 in the treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 574-8	63
529	Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3340-8	175
528	De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3340-8	617
527	[Therapeutic innovations in chronic inflammatory bowel diseases with "biological therapy"--anti-TNF and more]. 2002 , 43, 1386-99	1
526	Monoclonal antibodies in immune and inflammatory diseases. 2002 , 13, 615-20	37
525	Les voies de blocage de l'interleukine-1 dans la polyarthrite rhumatoïde. 2002 , 69, 685-688	1
524	[Recommendations of the Deutschen Gesellschaft für Rheumatologie on therapy of rheumatoid arthritis with the interleukin-1-receptor-antagonist Akakinra (KINERET)]. 2002 , 61, 698-700	2
523	[Phlegmon of the forearm due to therapy with Anakinra (interleukin-1 receptor-antagonist)]. 2003 , 62, 566-9	3
522	T-Zelltoleranz und Autoimmunität. 2003 , 44, 146-152	
521	Infections and biological therapy in rheumatoid arthritis. 2003 , 17, 345-63	64
520	Pharmacological treatment of established rheumatoid arthritis. 2003 , 17, 811-29	22
519	Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 339-47	101
518	Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2670-81	157
517	Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2949-58	37
516	Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3308-19	77
515	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3328-37	86
514	Pharmacokinetics of anakinra in subjects with different levels of renal function. 2003 , 74, 85-94	85
513	Cytokines in orthopaedic practice: a review. 2003 , 17, 378-385	6

512	[Assessment of the studies. Important recombinant agents in treatment of rheumatoid arthritis]. 2003 , 32, 396-403	
511	Therapeutic strategies for rheumatoid arthritis. 2003 , 2, 473-88	584
510	Modalit�s actuelles de la prise en charge th�rapeutique des arthrites juv�niles idiopathiques. 2003 , 70, 500-506	
509	Infection complications associated with the use of biologic agents. 2003 , 29, 185-202	80
508	Cytokine levels during symptomatic viral upper respiratory tract infection. 2003 , 91, 362-7	13
507	Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. 2003 , 348, 2583-4	580
506	Antibody therapy for rheumatoid arthritis. 2003 , 3, 323-8	65
505	The biology of TNF blockade. 2003 , 2, 346-57	81
504	Interleukin-1 receptor antagonist [IL-1F3]. 2003 , 669-708	9
503	Allergic rhinitis and polymorphisms of the interleukin 1 gene complex. 2003 , 91, 275-9	27
502	Immunotherapy for autoimmune and inflammatory renal diseases. 2003 , 3, 487-500	2
501	Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. 2003 , 62, 952-6	130
500	Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. 2003 , 197, 537-42	165
499	Bringing the clinical experience with anakinra to the patient. 2003 , 42 Suppl 2, ii36-40	4
498	Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. 2003 , 42 Suppl 2, ii22-8	36
497	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). 2003 , 62 Suppl 2, ii2-9	35
496	Addressing the safety of anakinra in patients with rheumatoid arthritis. 2003 , 42 Suppl 2, ii29-35	18
495	Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). 2003 , 12, 19-28	3

494	Imaging in rheumatoid arthritis--why MRI and ultrasonography can no longer be ignored. 2003 , 32, 63-73	70
493	New concepts in the treatment of rheumatoid arthritis. 2003 , 54, 197-216	58
492	Potential new drugs for therapy of chronic obstructive pulmonary disease. 2003 , 12, 1067-86	10
491	Computational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades. <i>Science Signaling</i> , 2003 , 2003, PE51	8.8 1
490	Manifestation in jedem Lebensalter - Rheumatoide Arthritis - Keine Alte-Leute-Krankheit. 2003 , 29, 340-346	
489	The role of interleukin-1 receptor antagonist in the prevention and treatment of disease. 2003 , 13, 1-6	2
488	Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. 2003 , 2, 347-65	14
487	Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?. 2003 , 15, 185-92	15
486	Upcoming biologic agents for the treatment of rheumatic diseases. 2003 , 15, 226-36	40
485	Fibromyalgia Syndrome: Canadian Clinical Working Case Definition, Diagnostic and Treatment ProtocolsA Consensus Document. 2003 , 11, 3-107	41
484	Infectious complications of biologic treatments of rheumatoid arthritis. 2003 , 15, 179-84	55
483	Rheumatoid arthritis. Targeted interventions can minimize joint destruction. 2003 , 114, 19-28	3
482	Progress in the treatment of rheumatic disease. 2003 , 18, 13-6	11
481	Biological therapy in IBD. Anti-tumor necrosis factor-alpha and others. 2003 , 21, 180-91	11
480	Rheumatoid arthritis: developing pharmacological therapies. 2004 , 13, 1007-18	19
479	Magnetic resonance imaging of the synovium in rheumatoid arthritis. 2004 , 8, 287-99	40
478	Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. 2004 , 43, 704-11	58
477	Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis. 2004 , 8, 375-90	3

476	Therapeutic potential of targeting IL-1 and IL-18 in inflammation. 2004 , 4, 847-60	22
475	A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. 2004 , 63, 1062-8	204
474	The impact of new biologicals in the treatment of rheumatoid arthritis. 2004 , 43 Suppl 3, iii17-iii23	36
473	Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. 2004 , 43, 640-7	79
472	The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. 2004 , 43 Suppl 3, iii2-iii9	145
471	Two is better than one? Combination therapy in rheumatoid arthritis. 2004 , 43, 1205-7	11
470	Therapeutic advances in rheumatoid arthritis. 2004 , 7, 62-70	2
469	Biological response modifiers. 2004 , 7, 179-183	1
468	Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. 2004 , 5, 380-7	113
467	Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. 2004 , 3, 330-9	163
466	Targeted gene therapy: frontiers in the development of 'smart drugs'. 2004 , 22, 304-10	16
465	The use of methotrexate in rheumatoid arthritis. 2004 , 34, 465-83	87
464	The treatment of rheumatoid arthritis. 2004 , 18, 507-38	10
463	Pharmaceutical treatment options for fibromyalgia. 2004 , 6, 274-80	11
462	Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. <i>Arthritis and Rheumatism</i> , 2004 , 50, 277-90	264
461	Counterpoint from the trenches: a pragmatic approach to therapeutic trials in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1344-7	8
460	Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1412-9	395
459	The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1752-60	72

458	Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2167-77	28
457	Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. 2004 , 3, 391-403	53
456	Functional genomics approaches in arthritis. 2004 , 4, 29-43	5
455	Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. 2004 , 6, 137-46	39
454	Clinical trials in rheumatic diseases: designs and limitations. 2004 , 30, 701-24, v-vi	17
453	The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. 2004 , 30, 365-80, vii	56
452	Anticytokine therapies in rheumatoid arthritis: from the pipette to the patient. 2004 , 1, 293-297	1
451	Therapeutic strategies for rheumatoid arthritis. 2004 , 350, 2591-602	416
450	New drugs for rheumatoid arthritis. 2004 , 350, 2167-79	527
449	Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. 2004 , 64, 1267-83	61
448	Durability and rapidity of response to anakinra in patients with rheumatoid arthritis. 2004 , 64, 2493-501	5
447	Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. 2004 , 5, 559-69	32
446	Anakinra: review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. 2004 , 26, 1960-75	131
445	Pathogenic roles of B cells in human autoimmunity; insights from the clinic. 2004 , 20, 517-27	179
444	Serious infections associated with anticytokine therapies in the rheumatic diseases. 2004 , 19, 320-34	93
443	Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. 2004 , 4, 307-15	19
442	[Bronchiolitis with airflow obstruction in adults]. 2004 , 25, 275-86	1
441	Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction. 2004 , 116, 14-6, 21-4	5

440	Bibliography Current World Literature. 2004 , 16, 293-327	
439	Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 , 16, 419-27	88
438	Biologic therapies on the horizon for rheumatoid arthritis. 2004 , 10, S32-9	14
437	Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 255-266	
436	[Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies]. 2004 , 59, 451-61	4
435	Beyond methotrexate: biologic therapy in rheumatoid arthritis. 2005 , 5, 222-6	7
434	Biologic therapies in clinical development for the treatment of rheumatoid arthritis. 2005 , 11, S45-54	29
433	Rheumatoid arthritis: non-tumor necrosis factor targets. 2005 , 17, 242-6	14
432	New advances in interleukin-1 blockade for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 447-454	
431	Pathogenesis of rheumatoid arthritis: targeting cytokines. 2005 , 1051, 716-29	120
430	Non-tumor necrosis factor biological therapies for rheumatoid arthritis. 2005 , 8, 77-83	2
429	Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics?. 2005 , 67, 1692-703	32
428	Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. 2005 , 153, 417-23	39
427	Rheumatic diseases: the effects of inflammation on bone. 2005 , 208, 228-51	301
426	Inflammatory arthritis in the era of the biologics. 2005 , 5, 19-44	3
425	The role of biologics in early rheumatoid arthritis. 2005 , 19, 179-89	4
424	The treatment of rheumatoid arthritis: getting better all the time?. <i>Arthritis and Rheumatism</i> , 2005 , 52, 991-4	9
423	Impact of managed care on the use of biologic agents for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 53, 423-30	7

422	Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2616-24	98
421	Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3015-9	24
420	Infections in patients with rheumatoid arthritis treated with biologic agents. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3403-12	526
419	Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3731-8	27
418	Fibromyalgia: progress in diagnosis and treatment. 2005 , 9, 399-404	19
417	The use of anakinra in juvenile arthritis. 2005 , 7, 434-40	36
416	Role of biological agents in immune-mediated inflammatory diseases. 2005 , 98, 192-204	31
415	Biological therapies of autoimmune diseases. 2005 , 4, 41-6	20
414	Inflammatory mediators as potential therapeutic targets in the spine. 2005 , 4, 257-66	19
413	A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. 2005 , 64, 38-43	49
412	Anti-cytokine therapy in systemic lupus erythematosus. 2005 , 14, 189-91	34
411	Treatment continuation in patients receiving biological agents or conventional DMARD therapy. 2005 , 64, 1274-9	103
410	Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. 2005 , 64, 630-3	79
409	Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. 2005 , 64, 1503-6	29
408	Treatment of fibromyalgia: a changing of the guard. 2005 , 1, 409-20	4
407	A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. 2005 , 44, 1414-21	102
406	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. 2005 , 64 Suppl 4, iv2-14	92
405	Rheumatoid arthritis: an overview of new and emerging therapies. 2005 , 45, 751-62	114

404	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. 2005 , 5, 519-29		4
403	Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. 2005 , 64, 881-5		39
402	Treatment of Rheumatoid Arthritis in the Elderly. 2005 , 35, 151-154		
401	Tratamiento de la artritis reumatoide. 2005 , 9, 1822-1829		
400	Tratamiento biológico de las enfermedades reumáticas. 2005 , 9, 1830-1839		
399	Infliximab for the treatment of early rheumatoid arthritis. 2005 , 5, 405-17		9
398	Monoclonal antibodies for immunological disorders: a review of recent patents. 2005 , 15, 1105-1114		
397	Anakinra: a review of its use in the management of rheumatoid arthritis. <i>BioDrugs</i> , 2005 , 19, 189-202	7.9	40
396	New insights into the biological therapy of Crohn's disease. 2005 , 15, 409-419		4
395	Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. 2005 , 175, 131-8		43
394	Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. 2005 , 31, 298-304		16
393	The combined effects of anti-TNF α antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane. 2005 , 32, 263-9		14
392	Improvement of collagen-induced arthritis by active immunization against murine IL-1 β peptides designed by molecular modelling. 2005 , 23, 4228-35		29
391	Subcutaneous Granuloma Annulare. 2005 , 55, 684-686		9
390	AR y AIJ. ¿Son más diferentes que semejantes?. 2005 , 6, 89-92		
389	Novel therapies for rheumatoid arthritis. 2005 , 12, 217-25		7
388	Unmet needs in rheumatoid arthritis. 2005 , 7 Suppl 3, S2-8		20
387	Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. 2006 , 8, R66		116

386	THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. 2006 , 8, R7	36
385	Autoinflammatory diseases: clinical and dermatologic features, genetics, pathogenesis and therapy. 2006 , 22, 67-90	4
384	New therapeutics in rheumatoid arthritis. 2006 , 32, 57-74, viii	10
383	Anakinra in the treatment of rheumatic disease. 2006 , 2, 331-40	13
382	Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. 2006 , 65, 760-2	41
381	[Not Available]. 2006 , 2, 78-89	9
380	[Not Available]. 2006 , 2, 114-5	
379	[Not Available]. 2006 , 2 Suppl 2, S52-9	20
378	Une nouvelle perspective thérapeutique dans le soulagement du patient arthrosique : un anti-IL-1 ?. 2006 , 7, 123-125	
377	Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?. 2006 , 32 Suppl 1, 21-8	9
376	Treatment of rheumatoid arthritis. 2006 , 63, 2451-65	118
375	Emerging therapies in juvenile rheumatoid/idiopathic arthritis. 2006 , 36, 97-103	4
374	Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment. 2006 , 2, 364-72	58
373	Inflammatory arthritides of the spine: surgical versus nonsurgical treatment. 2006 , 443, 208-21	12
372	Present and future of combination therapy of autoimmune diseases. <i>Future Rheumatology</i> , 2006 , 1, 649-655	
371	Signalling platforms that modulate the inflammatory response: new targets for drug development. 2006 , 5, 864-76	74
370	Joint inflammation and cytokine inhibition in rheumatoid arthritis. 2006 , 6, 13-9	80
369	Combination therapy for rheumatoid arthritis in the era of biologicals. 2006 , 2, 30-41	13

368	Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. 2006 , 23, 208-17	32
367	New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. 2006 , 11, 952-6	12
366	Is IL-1 a good therapeutic target in the treatment of arthritis?. 2006 , 20, 879-96	121
365	Systemic rheumatoid vasculitis: a review. 2006 , 36, 88-98	131
364	The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. <i>Arthritis and Rheumatism</i> , 2006 , 54, 600-6	103
363	Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2872-85	25
362	Adalimumab in the treatment of rheumatoid arthritis. 2006 , 2, 533-545	5
361	Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. 2006 , 65, 227-33	39
360	Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. 2006 , 65, 1602-7	30
359	The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. 2006 , 65, 342-7	58
358	An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. 2006 , 65, 538-41	5
357	Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). 2006 , 45, 491-2	58
356	Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. 2006 , 95, 246-9	44
355	InforMatrix: treatment of rheumatoid arthritis using biologicals. 2006 , 7, 1769-89	2
354	Novel therapies for rheumatoid arthritis. 2006 , 15, 1427-41	15
353	Safety of extended treatment with anakinra in patients with rheumatoid arthritis. 2006 , 65, 1006-12	211
352	Application of cellular gene therapy for rheumatoid arthritis. 2006 , 16, 269-275	15
351	Leflunomide in the treatment of rheumatoid arthritis. 2006 , 2, 17-31	7

350	The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. 2007 , 46, 1140-7	84
349	Emerging biologics in the treatment of uveitis. 2007 , 3, 781-96	3
348	NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. 2007 , 13, 1584-90	34
347	Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions. <i>Future Rheumatology</i> , 2007 , 2, 353-360	
346	Interleukin-1 in Rheumatoid Arthritis: Its Inhibition by IL-1Ra and Anakinra. 2007 , 23, 86-94	2
345	Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. 2007 , 29, 1071-85	9
344	New therapies for treatment of rheumatoid arthritis. 2007 , 370, 1861-74	706
343	[Treatment of rheumatoid arthritis with anakinra: a systematic review]. 2007 , 3, 153-8	5
342	Biologics in General Medicine. 2007 ,	1
341	Abatacept: a novel treatment for rheumatoid arthritis. 2007 , 8, 2371-9	7
340	Treatment of Rheumatoid Arthritis With Anakinra: A Systematic Review. 2007 , 3, 153-158	
339	It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3884-6	7
338	Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice. 2007 , 37, 2753-63	7
337	Quelle est la place actuelle de l'IL-1Ra dans les maladies rhumatismales?. 2007 , 74, 435-439	3
336	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. 2007 , 26, 1237-54	110
335	Biologic therapies in rheumatology: lessons learned, future directions. 2007 , 6, 75-92	141
334	Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. 2007 , 37, 591-600	29
333	The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. 2007 , 149, 217-25	297

332	Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors. 2007 , 220, 237-50	60
331	What is the role for interleukin-1 receptor antagonist in rheumatic disease?. 2007 , 74, 223-6	14
330	Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. 2007 , 95, 246-249	1
329	[Cytokines]. 2007 , 66, 297-8, 300-3	2
328	Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. 2007 , 59, 1084-92	19
327	New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. 2007 , 63, 879-89	12
326	P2 purinergic receptor modulation of cytokine production. 2007 , 3, 27-38	38
325	Treatment of osteoarthritis with anakinra. 2007 , 9, 31-5	24
324	Advances in the diagnosis and immunotherapy for ocular inflammatory disease. 2008 , 30, 145-64	23
323	Biologics in rheumatology: Austrian experiences from a rheumatic outpatient clinic. 2008 , 29, 69-73	2
322	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. 2008 , 5, 22	48
321	Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery. 2008 , 14, 1406-12	21
320	Local administration of interleukin-1 receptor antagonist inhibits deterioration of mechanical properties of the stress-shielded patellar tendon. 2008 , 41, 884-9	9
319	Biologic treatments for systemic rheumatic diseases. 2008 , 14, 206-16	15
318	Cytokines and anti-cytokines as therapeutics--an update. 2008 , 579, 1-12	118
317	A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. 2008 , 47, 1266-73	36
316	Clinical Trials in Rheumatoid Arthritis and Osteoarthritis. 2008 ,	1
315	Cytokines as therapeutic targets: advances and limitations. 2008 , 28, 440-4	65

314	Tocilizumab for rheumatoid and juvenile idiopathic arthritis. 2008 , 371, 961-3	17
313	The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. 2008 , 17, 349-59	76
312	[Wells' cellulitis and bacterial necrotizing cellulitis induced by anakinra]. 2008 , 135, 839-42	3
311	Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. 2008 , 17, 641-59	48
310	Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis. 2008 , 5, 189-99	4
309	Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. 2008 , 9, 381-93	18
308	Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. 2008 , 67, 238-43	58
307	Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. 2008 , 47, 1384-8	19
306	Targeted therapy in rheumatoid arthritis. 2008 , 3, 329-42	
305	Biologics and heart failure in rheumatoid arthritis: are we any wiser?. 2008 , 20, 327-33	26
304	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. 2008 , 2, 229-52	16
303	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. 2009 , 1, 17-35	3
302	Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. 2009 , 1, 163-178	3
301	Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. 2009 , 485	2
300	Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. 2009 , 1, 339-47	75
299	A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. 2009 , 181, 787-96	177
298	Efficacy of biologics in the treatment of rheumatoid arthritis. a meta-analysis. 2009 , 83, 1-9	31
297	Riloncept for the treatment of cryopyrin-associated periodic syndromes (CAPS). 2009 , 9, 519-31	50

296	Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. 2009 , 182, 547-53	55
295	2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations. 2009 , 4, 1939-48	28
294	Novel therapeutic targets along the Th17 pathway. 2009 , 39, 670-5	15
293	Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. 2009 , 28, 129-37	107
292	Limits of add-on trials: antirheumatic drugs. 2009 , 65, 33-41	7
291	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. 2009 , 8, 150-62	7
290	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. 2009 , 8, 371-89	15
289	Blocking interleukin-1 in rheumatic diseases. 2009 , 1182, 111-23	73
288	[Recommendations on therapy using interleukin-1beta-blocking agents]. 2009 , 68, 766-71	0
287	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. 2009 , 5, 578-82	275
286	Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. 2009 , 68, 25-32	356
285	Experimental arthritis: effect on growth parameters and total skeletal calcium. 2009 , 19, 442-6	2
284	Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. 2009 , 21, 242-53	226
283	Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. 2009 , 18, 269-76	83
282	[Biotherapy of auto-immune diseases : past, present and future perspectives]. 2009 , 38, 749-60	2
281	[Indications of anakinra]. 2009 , 38, 799-807	11
280	Allogeneic intra-bone marrow transplantation prevents rheumatoid arthritis in SKG/Jcl mice. 2009 , 32, 216-22	12
279	[Gene polymorphisms and pharmacogenetics in Rheumatoid Arthritis]. 2009 , 5, 268-79	2

278	Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. <i>BioDrugs</i> , 2009 , 23, 111-24	7.9	58
277	Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. 2009 , 5, 268-279		1
276	Anakinra for rheumatoid arthritis. 2009 , CD005121		94
275	Downregulation of heat shock protein 70 protects rheumatoid arthritis fibroblast-like synoviocytes from nitric oxide-induced apoptosis. 2009 , 11, R130		21
274	Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. 2009 , 11, R26		68
273	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93		19
272	Stakeholder Satisfaction with the Australian Rheumatology Association Database (ARAD). 2009 , 2, 61-8		1
271	Anakinra for rheumatoid arthritis: a systematic review. 2009 , 36, 1118-25		233
270	Biotechnological Approaches for the Treatment of Inflammatory Diseases. 2009 , 8, 51-71		1
269	Anti-cytokine targeted therapies for ANCA-associated vasculitis. 2010 ,		1
268	IL-1 pathways in inflammation and human diseases. 2010 , 6, 232-41		492
267	[IL-1 antagonists]. 2010 , 69, 581-93		0
266	State-of-the-art: rheumatoid arthritis. 2010 , 69, 1898-906		215
265	An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). 2010 , 29, 1169-73		41
264	The risk of infections with biologic therapies for rheumatoid arthritis. 2010 , 39, 327-46		204
263	Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. 2010 , 626, 219-28		51
262	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. 2010 , 24, 457-61		1
261	Management of Established Rheumatoid Arthritis. 2010 , 27-37		

260	Biologic Agents for Treatment of Rheumatoid Arthritis. 2010 , 9, 8-23	1
259	Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndrome. 2010 , 2, 57-72	3
258	Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis. 2010 , 9, 24-34	4
257	Rheumatoid arthritis therapy: advances from bench to bedside. 2010 , 43, 478-92	24
256	Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. 2010 , 36, 385-404	132
255	[Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis]. 2010 , 6, 23-36	62
254	Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. 2010 , 6, 23-36	0
253	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2010 , 69, 964-75	1210
252	Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. 2010 , 69, 976-86	319
251	The efficacy and safety of golimumab in the treatment of arthritis. 2010 , 10, 1131-43	2
250	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. 2011 , 70, 1575-80	157
249	IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. 2011 , 63, 30-44	25
248	Bioterapias en reumatología. 2011 ,	
247	Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. 2011 , 134, 928-46	45
246	Bioterapias en los reumatismos inflamatorios. 2011 , 13, 1-7	
245	Adverse effects of biologics: a network meta-analysis and Cochrane overview. 2011 , CD008794	353
244	[IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy]. 2004 , 56, 62-73	7
243	[Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis]. 2007 , 59, 32-7	17

242	[Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects]. 2003 , 55, 224-35	0
241	[The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis]. 2004 , 56, 74-9	3
240	[Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience]. 2005 , 57, 44-51	6
239	[Reconstructing the pyramid as a therapeutic approach to rheumatoid arthritis]. 2004 , 56, 46-50	
238	Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis. 2011 , 49, 290-6	28
237	Osteoarthritis-like damage of cartilage in the temporomandibular joints in mice with autoimmune inflammatory arthritis. 2011 , 19, 458-65	20
236	Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. 2011 , 31, 39-51	45
235	Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. 2011 , 33, 679-707	185
234	Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. 2011 , 22, 1023-36	30
233	Ablation of the Ccr2 gene exacerbates polyarthritis in interleukin-1 receptor antagonist-deficient mice. <i>Arthritis and Rheumatism</i> , 2011 , 63, 96-106	7
232	Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. <i>Arthritis and Rheumatism</i> , 2011 , 63, 840-9	117
231	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. <i>Arthritis and Rheumatism</i> , 2011 , 63, 600-9	307
230	American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2151-6	21
229	Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. 2011 , 70, 858-63	19
228	Inflammasome activation in reperfusion injury: friendly fire on myocardial infarction?. 2011 , 123, 574-6	14
227	Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. 2011 , 32, 517-27	83
226	Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). 2011 , 4, 1-10	35
225	MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. 2011 , 70, 2075-2081	48

224	Gene profiling predicts rheumatoid arthritis responsiveness to IL-1Ra (anakinra). 2011 , 50, 283-92	21
223	XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1-mediated diseases. 2011 , 3, 49-60	58
222	Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. 2012 , 39, 720-7	159
221	A bispecific antibody against IL-1 and IL-17A is beneficial for experimental rheumatoid arthritis. 2012 , 14, 770-8	22
220	Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. 2012 , 14, 217	94
219	Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. 2012 , 308, 898-908	209
218	Biological agents for the treatment of uveitis. 2012 , 12, 311-28	25
217	Glucocorticoids, Inflammation, and Bone. 2012 , 113-131	
216	Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor production and Th17 cell differentiation. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2896-906	31
215	Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. 2012 , 46, 1491-505	15
214	Paeoniflorin inhibits function and down-regulates HLA-DR and CD80 expression of human peripheral blood monocytes stimulated by rhIL-1. 2012 , 14, 172-8	13
213	Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. 2012 , 32, 3277-9	57
212	Targeting the hinge glycine flip and the activation loop: novel approach to potent p38 inhibitors. 2012 , 55, 7862-74	29
211	Bone-Metabolic Functions and Modulators. 2012 ,	0
210	Milnacipran Hydrochloride in the Treatment of Fibromyalgia Syndrome: Safety, Efficacy and Tolerability. 2012 , 4, CMT.S2247	
209	Biologic Agent for Rheumatoid Arthritis. 2012 , 32, 68	2
208	Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. 2012 , 32, 749-57	7
207	Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. 2012 , 32, 683-90	67

206	Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. 2012 , 32, 727-64	23
205	Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. 2012 , 32, 295-9	78
204	Emerging therapies for rheumatoid arthritis. 2013 , 18, 231-44	11
203	Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. 2013 , 22, 3192-202	155
202	Different effects of biological drugs in rheumatoid arthritis. 2013 , 12, 575-9	66
201	[Interleukin-1 and the interleukin-1 receptor antagonist gene polymorphisms study in patients with rheumatoid arthritis]. 2013 , 61, 264-8	7
200	Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents. 2013 , 23, 5870-3	18
199	A critical role for interleukin-1 in the progression of autoimmune diseases. 2013 , 17, 658-69	58
198	Post-treatment lyme syndrome and central sensitization. 2013 , 25, 176-86	18
197	Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. 2013 , 15, R64	50
196	The role of cytokines in inflammatory bone loss. 2013 , 42, 555-622	161
195	Ameliorative effect of <i>Drynaria quercifolia</i> (L.) J. Sm., an ethnomedicinal plant, in arthritic animals. 2013 , 51, 356-63	8
194	Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. 2013 , 75, 197-207	70
193	Inflammasome and cytokine blocking strategies in autoinflammatory disorders. 2013 , 147, 242-75	59
192	Therapies for active rheumatoid arthritis after methotrexate failure. 2013 , 369, 307-18	251
191	Caspase functions in cell death and disease. 2013 , 5, a008656	1160
190	Monoclonal antibodies in rheumatoid arthritis. 2013 , 8, 541-556	7
189	In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET. 2013 , 54, 151-8	20

188	Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. 2013 , 42, 190-5	37
187	Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases. 2013 , 2013, 808125	15
186	IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. 2013 , 9, e1003243	110
185	Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. 2014 , 8, 1-12	19
184	Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. 2013 , 78, 545-53	21
183	Inhibition of Toll-like receptor-mediated inflammation in vitro and in vivo by a novel benzoxaborole. 2013 , 344, 436-46	12
182	Selected Topics in Rheumatoid Arthritis. 2013 , 27-38	
181	Pharmacotherapy options in rheumatoid arthritis. 2013 , 6, 35-43	68
180	Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. 2013 , 5, 21-32	2
179	Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis. 2013 , 19, 183-94	17
178	Anakinra in the treatment of rheumatoid arthritis in adult patients with an inadequate response to methotrexate. Systematic review and meta-analysis. 2013 , 2, 119-126	
177	Treatment of Rheumatoid Arthritis with Biological Agents. 2013 ,	1
176	Interleukin-1 receptor blockade in perinatal brain injury. 2014 , 2, 108	31
175	Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. 2014 , 5, 516-36	50
174	Evaluation of anakinra for the treatment of systemic juvenile idiopathic arthritis. 2014 , 2, 181-188	
173	Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. 2014 , 41, 1935-43	21
172	Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice. 2014 , 171, 3526-38	36
171	Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis. 2014 , 66, 998-1007	4

170	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. 2014 , 73, 1755-60	10
169	Purinergic receptor P2X ₁ α novel target for anti-inflammatory therapy. 2014 , 22, 54-88	70
168	Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model. 2014 , 21, 119-27	16
167	Emerging role of leptin in rheumatoid arthritis. 2014 , 177, 557-70	52
166	The degree of CD4+ T cell autoreactivity determines cellular pathways underlying inflammatory arthritis. 2014 , 192, 3043-56	4
165	Tuberculosis risk in patients treated with non-anti-tumor necrosis factor- α targeted biologics and recently licensed TNF- α inhibitors: data from clinical trials and national registries. 2014 , 91, 56-64	63
164	Dual inhibition of interleukin-1 β and interleukin-18: a new treatment option for sepsis?. 2014 , 189, 242-4	4
163	Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. 2014 , 6, 379-93	31
162	Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. 2015 , 10, e0137258	13
161	The inflammasome and IL-1 β implications for the treatment of inflammatory diseases. 2015 , 7, 243-54	40
160	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. 2015 , 11, 276-89	265
159	Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis. 2015 , 42, 121-33	16
158	Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. 2015 , 67, 280-309	224
157	Evasion of inflammasome activation by microbial pathogens. 2015 , 125, 469-77	41
156	Combination conventional DMARDs compared to biologicals: what is the evidence?. 2015 , 27, 183-8	8
155	IL-17-producing $\gamma\delta$ T cells are regulated by estrogen during development of experimental arthritis. 2015 , 161, 324-32	16
154	Treatment of rheumatoid arthritis: Unraveling the conundrum. 2015 , 65, 1-18	73
153	Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. 2015 , 14, 1-9	70

152	Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. <i>Frontiers in Immunology</i> , 2016 , 7, 11	8.4	22
151	New therapeutic approaches in rheumatoid arthritis. 2016 , 45, e179-92		4
150	Anti-inflammatory Effect of Methyl Gallate on Experimental Arthritis: Inhibition of Neutrophil Recruitment, Production of Inflammatory Mediators, and Activation of Macrophages. 2016 , 79, 1554-66		38
149	An update on dietary phenolic compounds in the prevention and management of rheumatoid arthritis. 2016 , 7, 2943-69		26
148	Amelioratory effect of flavonoids rich Pergularia daemia extract against CFA induced arthritic rats. 2016 , 80, 244-252		18
147	MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. 2016 , 14, 1204-1216		9
146	Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis. 2016 , 56, 835-44		13
145	Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. 2016 , 55, 1499-506		78
144	Therapeutic effect of dioscin on collagen-induced arthritis through reduction of Th1/Th2. 2016 , 39, 79-83		17
143	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). 2016 , 11, CD012437		18
142	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. 2016 , 68, 1478-88		37
141	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. 2016 , CD012183		36
140	Interleukin-1 function and role in rheumatic disease. 2016 , 12, 14-24		157
139	Cytokine inhibitors. 2016 , 39-69		
138	Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. 2016 , 43, 495-503		28
137	IL-1 receptor antagonist (IL-1Ra)-Fc ameliorate autoimmune arthritis by regulation of the Th17 cells/Treg balance and arthrogenic cytokine activation. 2016 , 172, 56-66		9
136	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. 2016 , 45, 519-32		41
135	A obesidade é um determinante da resistência à insulina mais importante do que os níveis circulantes de citocinas pró-inflamatórias em pacientes com artrite reumatoide. 2017 , 57, 320-329		2

134	Selected cytokine pathways in rheumatoid arthritis. 2017 , 39, 365-383		147
133	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. 2017 , 3, CD012591		29
132	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. 2017 , 5, CD012657		33
131	Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. 2017 , 37, 1423-1434		18
130	The inhibition of NLRP3 signaling attenuates liver injury in an α -galactosylceramide-induced hepatitis model. 2017 , 490, 364-370		3
129	Tratamiento de la artritis reumatoide. 2017 , 12, 1626-1638		2
128	Obesity is the main determinant of insulin resistance more than the circulating pro-inflammatory cytokines levels in rheumatoid arthritis patients. 2017 , 57, 320-329		5
127	Senescent cells: an emerging target for diseases of ageing. 2017 , 16, 718-735		488
126	Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. 2017 , 131, 2241-2256		32
125	Systems Pharmacology Dissection of Multiscale Mechanisms of Action for Herbal Medicines in Treating Rheumatoid Arthritis. 2017 , 14, 3201-3217		23
124	Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. 2017 , 69, 854-862		100
123	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2017 , 958-982.e7		2
122	Myostatin Promotes Interleukin-1 β Expression in Rheumatoid Arthritis Synovial Fibroblasts through Inhibition of miR-21-5p. <i>Frontiers in Immunology</i> , 2017 , 8, 1747	8.4	36
121	Beneficial effect of 20-hydroxyecdysone exerted by modulating antioxidants and inflammatory cytokine levels in collagen-induced arthritis: A model for rheumatoid arthritis. 2017 , 16, 6162-6169		5
120	Treatment of Rheumatoid Arthritis. 2017 , 1187-1212.e5		
119	Lung Disease in Rheumatoid Arthritis. 2018 ,		
118	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. 2018 , 121-161		2
117	Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. <i>Science Signaling</i> , 2018 , 11,	8.8	19

116	Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. 2018 , 16, 1374-1384	59
115	Subcutaneous administration of a neutralizing IL-1 β antibody prolongs limb allograft survival. 2018 , 18, 2029-2042	4
114	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). 2018 , 24 Suppl 2, S21-S40	114
113	Exenatide Increases IL-1RA Concentration and Induces Nrf-2-Keap-1-Regulated Antioxidant Enzymes: Relevance to Cell Function. 2018 , 103, 1180-1187	10
112	NFB-Mediated Invasiveness in CD133 Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling. 2018 , 16, 162-172	33
111	Host target-based approaches against arboviral diseases. 2018 , 399, 203-217	1
110	Anakinra Therapy for Non-cancer Inflammatory Diseases. 2018 , 9, 1157	137
109	IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial. 2018 , 103, 3466-3476	21
108	Mechanistic immunological based classification of rheumatoid arthritis. 2018 , 17, 1115-1123	34
107	Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. 2018 , 37, 3381-3386	11
106	Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. 2018 , 38, 1363-1383	24
105	Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. 2018 , 17, 727-732	57
104	Inhibition of Tubulin Chain May Play a Regulatory Role in the Development of Rheumatoid Arthritis. 2019 , 44, 128-135	0
103	The connection between the Th17 cell related cytokines and cancer stem cells in cancer: Novel therapeutic targets. 2019 , 213, 9-20	8
102	Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis. 2019 , 2, e1913102	11
101	Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects. 2019 , 44, 719-721	1
100	New therapies in development for the management of non-infectious uveitis: A review. 2019 , 47, 396-417	26
99	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. 2019 , 9, e023765	17

98	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases. 2019 , 751-774	
97	Anakinra in children and adults with Still's disease. 2019 , 58, vi9-vi22	42
96	The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. 2019 , 144, 334-344	10
95	Strategies toward rheumatoid arthritis therapy; the old and the new. 2019 , 234, 10018-10031	134
94	Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects. 2019 , 44, 353-360	3
93	Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?. 2019 , 118, 8-18	11
92	Cytokine targeting in rheumatoid arthritis. 2019 , 206, 3-8	11
91	Hand Rheumatoid Arthritis. 2020 , 179-184	
90	Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials. 2020 , 59, 709-717	10
89	PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. 2020 , 295, 868-882	4
88	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. 2020 , 16, 32-52	36
87	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374	9
86	Inhibition of interleukin-1 β signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis. 2020 , 9, e1206	3
85	Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. 2020 , 10, 589908	5
84	Anti-cytokine targeted therapies for ANCA-associated vasculitis. 2020 , 9, CD008333	3
83	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. 2020 , 33,	32
82	Interleukin 1 β mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP. 2020 , 10, 3833-3848	16
81	Precision medicine and management of rheumatoid arthritis. 2020 , 110, 102405	22

80	Cellular senescence in ageing: from mechanisms to therapeutic opportunities. 2021 , 22, 75-95	191
79	Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. 2021 , 13, 1759720X211002685	1
78	Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. 2021 , 10, e2002214	5
77	Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis. 2021 , 22, 803-815	0
76	The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. 2021 , 12, 680043	9
75	Biomarker Approach Towards Rheumatoid Arthritis Treatment. 2021 , 17, 162-175	0
74	Fusion proteins of biologic agents in the treatment of rheumatoid arthritis (RA): A network meta-analysis. 2021 , 100, e26350	
73	A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. 2021 , 73, 1533-1542	7
72	IL-1 β -Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. 2021 , 74, 3174-3193	10
71	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. 2021 , 385, 628-639	26
70	Therapeutic human monoclonal antibodies in inflammatory diseases. 2014 , 1060, 37-59	39
69	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. 2008 , 169-185	1
68	Application of cellular gene therapy for rheumatoid arthritis. 2006 , 16, 269-75	6
67	Rheumatic Diseases. 2006 , 1383-1408	2
66	Tuberculosis and SLE-Like Symptoms as a Complication of Biological Anti-TNF Therapy. 2004 , 623-628	1
65	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143	4
64	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2013 , 917-940.e6	2
63	Treatment of Rheumatoid Arthritis. 2013 , 1137-1160.e4	2

62	PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. 2020 , 295, 868-882	6
61	Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial. 2019 , 8, 701-708	3
60	Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. 2009 , 3, 485-98	17
59	The role of a chemokine receptor, CCR2, in suppressing the development of arthritis in IL-1 receptor antagonist-deficient mice. 2012 , 32, 124-131	2
58	Therapeutic strategies in the treatment of periodontitis. 2012 , 58, 3-14	1
57	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. 2020 , 35, 41-59	10
56	Biologic Agents in Rheumatic Diseases. 2012 , 82, 549	3
55	The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. 2020 , 27, 4	9
54	Biological agents targeting beyond TNF-alpha. 2008 , 12, 181-9	7
53	A Systemic-Onset Juvenile Idiopathic Arthritis Patient with Reduced Anakinra Treatment Admitted with an Attack. 2017 , 49, 69-71	1
52	Bioterapias en los reumatismos inflamatorios. 2021 , 23, 1-11	
51	Wirksamkeit und Sicherheit von rekombinantem IL-1-Rezeptor-Antagonisten bei Patienten mit rheumatoider Arthritis. 2002 , 37-49	
50	Basistherapeutika und Immunsuppressiva. 2003 , 706-749	
49	Targeted IL-1 inhibition. 2004 , 69-87	
48	Neue Arzneimittel. 2004 , 24-87	6
47	The clinical use of anti-cytokine therapy in rheumatic diseases. 2004 , 107-125	
46	Anakinra in rheumatoid arthritis. 2005 , 279-291	
45	Targeting DMARD therapy. 2005 , 25-47	

- 44 Combination therapy. **2005**, 293-318
- 43 A. **2007**, 3-25
- 42 [p38 MAP Kinase inhibitor]. *Japanese Journal of Clinical Immunology*, **2007**, 30, 390-7
- 41 Rheumatoid arthritis and the evolution of therapy: from symptomatic to bench-to-bedside biological drugs. *Future Rheumatology*, **2007**, 2, 143-152
- 40 Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2009**, 883-907 ○
- 39 IL-1 Inhibitors in the Treatment of Rheumatoid Arthritis. **2009**, 350-355
- 38 Biologic Therapies In Rheumatoid Arthritis. **2009**,
- 37 Corneal Disease in Rheumatoid Arthritis. **2011**, 1117-1132 1
- 36 Arthritic Disorders. **2011**, 632-650
- 35 Cytokine neutralizers. **2011**, 571-576.e2
- 34 Les traitements ciblant IL-1: quelles maladies?. **2011**, 123-130
- 33 Nonsteroidal Anti-inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, and Agents Used in Gout. **2012**, 415-475 1
- 32 Therapeutic Strategies to Treat Alcohol-Related Disorders Targeting Central Immune Signaling. **2013**, 535-559
- 31 Cytokine neutralizers. **2015**, 479-484 1
- 30 Rheumatoid Arthritis. **2016**, 517-544
- 29 Therapeutic effect of Vitamin E in preventing bone loss: An evidence-based review. *International Journal for Vitamin and Nutrition Research*, **2019**, 89, 357-370 1.7 3
- 28 Inflammatory Arthritis: Rheumatoid Arthritis. **2020**, 676-688
- 27 Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. *Cells*, **2021**, 10, 7.9 6

26	Computational Design of Variant TNF Molecules: A Novel Methodology for Inhibition of Proinflammatory Cascades. <i>Science Signaling</i> , 2003 , 2003, pe51-pe51		8.8	
25	Anticytokine Treatment. 2007 , 437-448			
24	Development of Biological Therapies for Inflammatory Arthritis. 2008 , 37-49			
23	Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 255-266			
22	New advances in interleukin-1 blockade for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 447-454			
21	Biologic Therapies for Rheumatoid Arthritis Targeting TNF- α and IL-1. 2007 , 111-123			1
20	A Review on Comparison of Effectiveness and Safety of Disease Modifying Anti-Rheumatoid Drugs Used in Patients with Rheumatoid Arthritis. <i>Journal of Drug Delivery and Therapeutics</i> , 2020 , 10, 207-212 ^{1,3}			
19	Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?. <i>American Journal of Translational Research (discontinued)</i> , 2017 , 9, 3758-3775	3		3
18	The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3		3
17	Senescence and the tumor-immune landscape: Implications for cancer immunotherapy.. <i>Seminars in Cancer Biology</i> , 2022 ,	12.7		2
16	Rheumatoid arthritis: immunogenetic factors and immune therapies. 2022 , 279-307			
15	Immunogenetic markers as prognostic tools for the management of various human diseases. 2022 , 57-87			
14	Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.. <i>Immune Network</i> , 2022 , 22, e8	6.1		0
13	Interleukin-1 β blockade reduces intestinal inflammation in a murine model of Tumor Necrosis Factor-independent ulcerative colitis.. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022 ,	7.9		1
12	Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis. <i>BioDrugs</i> ,	7.9		1
11	Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. 2022 , 108228			0
10	The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022 , 60, 280-298	0.9		2
9	Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 13,	8.4		4

- 8 Osteoimmunology in periodontitis; a paradigm for Th17/IL-17 inflammatory bone loss. **2022**, 163, 116500 ○
- 7 Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist. **2022**, 14, 1785 ○
- 6 Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series. **2022**, 3, 603-611.e2 ○
- 5 Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain. **2022**, 163, S79-S98 ○
- 4 Validation of traditional claims of anti-arthritic efficacy of trans-Himalayan snow mountain garlic (*Allium ampeloprasum* L.) extract using adjuvant-induced arthritis rat model: A comparative evaluation with normal garlic (*Allium sativum* L.) and dexamethasone. **2023**, 303, 115939 ○
- 3 Interleukin-1 Targeted Agents. **2022**, 173-185 ○
- 2 Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseasesRA as a role model. **2022**, 42, ○
- 1 The Evolution of TNF-Blockade for the Treatment of Rheumatoid Arthritis. **2022**, 16, ○